Identifying the mechanisms underlying the protective effect of tetramethylpyrazine against cisplatin‑induced in vitro ototoxicity in HEI‑OC1 auditory cells using gene expression profiling

Guan,Guofang; He,Xiao; Chen,Jingjing; Bin,Li; Tang,Xuxia

doi:10.3892/mmr.2020.11631

Identifying the mechanisms underlying the protective effect of tetramethylpyrazine against cisplatin‑induced in vitro ototoxicity in HEI‑OC1 auditory cells using gene expression profiling

Authors:
- Guofang Guan
- Xiao He
- Jingjing Chen
- Li Bin
- Xuxia Tang
View Affiliations

Affiliations: Department of Otolaryngology, The Second Hospital of Jilin University, Changchun, Jilin 130041, P.R. China, Department of Otolaryngology, The First Affiliated Hospital of Zhejiang Traditional Chinese Medical University, Hangzhou, Zhejiang 310006, P.R. China
Published online on: October 23, 2020 https://doi.org/10.3892/mmr.2020.11631
Pages: 5053-5068
Copyright: © Guan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Sensorineural hearing loss is prevalent in patients receiving cisplatin therapy. Tetramethylpyrazine (Tet) and tanshinone IIA (Tan IIA) have protective roles against hearing impairment or ototoxicity. The present study aimed to investigate the molecular mechanisms underlying cisplatin‑induced ototoxicity and the protective effect of Tet and Tan IIA against it. House Ear Institute‑Organ of Corti 1 auditory cells were treated with titrating doses of Tan IIA, Tet, and cisplatin. In a cell viability assay, cisplatin, Tan IIA and Tet had IC50 values of 42.89 µM, 151.80 and 1.04x103 mg/l, respectively. Tan IIA augmented cisplatin‑induced cytotoxicity. However, Tet concentrations <75 mg/l attenuated cisplatin‑induced cytotoxicity and apoptosis. Moreover, RNA sequencing analysis was carried out on auditory cells treated for 30 h with 30 µM cisplatin alone for 48 h or combined with 37.5 mg/l Tet for 30 h. Differentially expressed genes (DEGs) induced in these conditions were identified and examined using Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway analysis. Cisplatin increased the expression of genes related to the p53 and FoxO pathways, such as Fas, p21/CDKN1A, and Bcl‑2 binding component 3, but decreased the expression of insulin‑like growth factor 1 (IGF1), as well as genes in the histone (Hist)1 and Hist2 clusters. Treatment with Tet downregulated FOXO3 and Bcl‑2 binding component 3, and increased the expression of IGF1. Moreover, Tet upregulated genes associated with Wnt signaling, but not p53‑related genes. Thus, the otoprotective properties of Tet might be mediated by activation of Wnt and IGF1 signaling, and inhibition of FoxO signaling.

View Figures

View References

1	Breglio AM, Rusheen AE, Shide ED, Fernandez KA, Spielbauer KK, McLachlin KM, Hall MD, Amable L and Cunningham LL: Cisplatin is retained in the cochlea indefinitely following chemotherapy. Nat Commun. 8:16542017. View Article : Google Scholar : PubMed/NCBI
2	Shorter P, Harden F, Owen R, Panizza B, Burmeister B, Sommerville J, Mengersen K and Foote M: Risk profiles for sensorineural hearing loss in patients with head and neck cancer receiving cisplatin-based chemoradiation. J Med Imaging Radiat Sci. 48:61–67. 2017. View Article : Google Scholar : PubMed/NCBI
3	Wang J, Chen YY, Tai A, Chen XL, Huang SM, Yang C, Bao Y, Li NW, Deng XW, Zhao C, et al: Sensorineural hearing loss after combined intensity modulated radiation therapy and cisplatin-based chemotherapy for nasopharyngeal carcinoma. Transl Oncol. 8:456–462. 2015. View Article : Google Scholar : PubMed/NCBI
4	Robertson MS, Hayashi SS, Camet ML, Trinkaus K, Henry J and Hayashi RJ: Asymmetric sensorineural hearing loss is a risk factor for late-onset hearing loss in pediatric cancer survivors following cisplatin treatment. Pediatr Blood Cancer. 66:e274942019. View Article : Google Scholar : PubMed/NCBI
5	Bass JK, Hua CH, Huang J, Onar-Thomas A, Ness KK, Jones S, White S, Bhagat SP, Chang KW and Merchant TE: Hearing loss in patients who received cranial radiation therapy for childhood cancer. J Clin Oncol. 34:1248–1255. 2016. View Article : Google Scholar : PubMed/NCBI
6	Wu X, Li X, Song Y, Li H, Bai X, Liu W, Han Y, Xu L, Li J, Zhang D, et al: Allicin protects auditory hair cells and spiral ganglion neurons from cisplatin-Induced apoptosis. Neuropharmacology. 116:429–440. 2017. View Article : Google Scholar : PubMed/NCBI
7	Sheth S, Mukherjea D, Rybak LP and Ramkumar V: Mechanisms of cisplatin-induced ototoxicity and otoprotection. Front Cell Neurosci. 11:3382017. View Article : Google Scholar : PubMed/NCBI
8	Liu W, Xu X, Fan Z, Sun G, Han Y, Zhang D, Xu L, Wang M, Wang X, Zhang S, et al: Wnt signaling activates TP53-induced glycolysis and apoptosis regulator and protects against cisplatin-induced spiral ganglion neuron damage in the mouse cochlea. Antioxid Redox Signal. 30:1389–1410. 2019. View Article : Google Scholar : PubMed/NCBI
9	Liu L, Chen Y, Qi J, Zhang Y, He Y, Ni W, Li W, Zhang S, Sun S, Taketo MM, et al: Wnt activation protects against neomycin-induced hair cell damage in the mouse cochlea. Cell Death Dis. 7:e21362016. View Article : Google Scholar : PubMed/NCBI
10	Guo X, Bai X, Li L, Li J and Wang H: Forskolin protects against cisplatin-induced ototoxicity by inhibiting apoptosis and ROS production. Biomed Pharmacother. 99:530–536. 2018. View Article : Google Scholar : PubMed/NCBI
11	Zhang Q, Liu H, McGee J, Walsh EJ, Soukup GA and He DZ: Identifying microRNAs involved in degeneration of the organ of corti during age-related hearing loss. PLoS One. 8:e627862013. View Article : Google Scholar : PubMed/NCBI
12	Wang P, Zhang P, Huang J, Li M and Chen X: Trichostatin a protects against cisplatin-induced ototoxicity by regulating expression of genes related to apoptosis and synaptic function. Neurotoxicology. 37:51–62. 2013. View Article : Google Scholar : PubMed/NCBI
13	Bhatta P, Dhukhwa A, Sheehan K, Al Aameri RFH, Borse V, Ghosh S, Sheth S, Mamillapalli C, Rybak L, Ramkumar V and Mukherjea D: Capsaicin protects against cisplatin ototoxicity by changing the STAT3/STAT1 ratio and activating Cannabinoid (CB2) receptors in the Cochlea. Sci Rep. 9:41312019. View Article : Google Scholar : PubMed/NCBI
14	Kitcher SR, Kirkwood NK, Camci ED, Wu P, Gibson RM, Redila VA, Simon JA, Rubel EW, Raible DW, Richardson GP and Kros CJ: ORC-13661 protects sensory hair cells from aminoglycoside and cisplatin ototoxicity. JCI Insight. 4:e1267642019. View Article : Google Scholar
15	Cui C, Liu D and Qin X: Attenuation of streptomycin ototoxicity by tetramethylpyrazine in guinea pig cochlea. Otolaryngol Head Neck Surg. 152:904–911. 2015. View Article : Google Scholar : PubMed/NCBI
16	Du S, Yao Q, Tan P, Xie G, Ren C, Sun Q, Zhang X, Zheng R, Yang K, Yuan Y and Yuan Q: Protective effect of tanshinone IIA against radiation-induced ototoxicity in HEI-OC1 cells. Oncol Lett. 6:901–906. 2013. View Article : Google Scholar : PubMed/NCBI
17	Bayram A, Kaya A, Akay E, Hıra İ and Özcan İ: The protective role of tetramethylpyrazine against cisplatin-induced ototoxicity. Int J Pediatr Otorhinolaryngol. 94:1–7. 2017. View Article : Google Scholar : PubMed/NCBI
18	Hou LL, Xu QJ, Hu GQ and Xie SQ: Synergistic antitumor effects of tanshinone II A in combination with cisplatin via apoptosis in the prostate cancer cells. Yao Xue Xue Bao. 48:675–679. 2013.(In Chinese). PubMed/NCBI
19	Chang TW, Lin CY, Tzeng YJ and Lur HS: Synergistic combinations of tanshinone IIA and trans-resveratrol toward cisplatin-comparable cytotoxicity in HepG2 human hepatocellular carcinoma cells. Anticancer Res. 34:5473–5480. 2014.PubMed/NCBI
20	Banday AR, Baumgartner M, Al Seesi S, Karunakaran DK, Venkatesh A, Congdon S, Lemoine C, Kilcollins AM, Mandoiu I, Punzo C and Kanadia RN: Replication-dependent histone genes are actively transcribed in differentiating and aging retinal neurons. Cell Cycle. 13:2526–2541. 2014. View Article : Google Scholar : PubMed/NCBI
21	Kadri Z, Lefevre C, Goupille O, Penglong T, Granger-Locatelli M, Fucharoen S, Maouche-Chretien L, Leboulch P and Chretien S: Erythropoietin and IGF-1 signaling synchronize cell proliferation and maturation during erythropoiesis. Genes Dev. 29:2603–2616. 2015.PubMed/NCBI
22	Yu M, Wang H, Xu Y, Yu D, Li D, Liu X and Du W: Insulin-like growth factor-1 (IGF-1) promotes myoblast proliferation and skeletal muscle growth of embryonic chickens via the PI3K/Akt signalling pathway. Cell Biol Int. 39:910–922. 2015. View Article : Google Scholar : PubMed/NCBI
23	Bruchim I, Attias Z and Werner H: Targeting the IGF1 axis in cancer proliferation. Expert Opin Ther Targets. 3:1179–1192. 2009. View Article : Google Scholar
24	Jeon JH, Kim SK, Kim HJ, Chang J, Ahn CM and Chang YS: Insulin-like growth factor-1 attenuates cisplatin-induced gammaH2AX formation and DNA double-strand breaks repair pathway in non-small cell lung cancer. Cancer Lett. 272:232–241. 2008. View Article : Google Scholar : PubMed/NCBI
25	Du J, Shi HR, Ren F, Wang JL, Wu QH, Li X and Zhang RT: Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells. BMC Cancer. 17:8512017. View Article : Google Scholar : PubMed/NCBI
26	Sun Y, Zheng S, Torossian A, Speirs CK, Schleicher S, Giacalone NJ, Carbone DP, Zhao Z and Lu B: Role of insulin-like growth factor-1 signaling pathway in cisplatin-resistant lung cancer cells. Int J Radiat Oncol Biol Phys. 82:e563–e572. 2012. View Article : Google Scholar : PubMed/NCBI
27	Chan D, Zhou Y, Chui CH, Lam KH, Law S, Chan AS, Li X, Lam AK and Tang JCO: Expression of insulin-like growth factor binding protein-5 (IGFBP5) reverses cisplatin-resistance in esophageal carcinoma. Cells. 7:1432018. View Article : Google Scholar
28	Liu S, Zhang X, Sun M, Xu T and Wang A: FoxO3a plays a key role in the protective effects of pomegranate peel extract against amikacin-induced ototoxicity. Int J Mol Med. 40:175–181. 2017. View Article : Google Scholar : PubMed/NCBI
29	Rupp M, Hagenbuchner J, Rass B, Fiegl H, Kiechl-Kohlendorfer U, Obexer P and Ausserlechner MJ: FOXO3-mediated chemo-protection in high-stage neuroblastoma depends on wild-type TP53 and SESN3. Oncogene. 36:6190–6203. 2017. View Article : Google Scholar : PubMed/NCBI
30	Fitzwalter BE and Thorburn A: FOXO3 links autophagy to apoptosis. Autophagy. 14:1467–1468. 2018. View Article : Google Scholar : PubMed/NCBI
31	Ma W, Li J, Hu J, Cheng Y, Wang J, Zhang X and Xu M: MiR214-regulated p53-NOX4/p66shc pathway plays a crucial role in the protective effect of Ginkgolide B against cisplatin-induced cytotoxicity in HEI-OC1 cells. Chem Biol Interact. 245:72–81. 2016. View Article : Google Scholar : PubMed/NCBI
32	Xiong H, Pang J, Yang H, Dai M, Liu Y, Ou Y, Huang Q, Chen S, Zhang Z, Xu Y, et al: Activation of miR-34a/SIRT1/p53 signaling contributes to cochlear hair cell apoptosis: Implications for age-related hearing loss. Neurobiol Aging. 36:1692–1701. 2015. View Article : Google Scholar : PubMed/NCBI
33	Benkafadar N, Menardo J, Bourien J, Nouvian R, François F, Decaudin D, Maiorano D, Puel JL and Wang J: Reversible p53 inhibition prevents cisplatin ototoxicity without blocking chemotherapeutic efficacy. EMBO Mol Med. 9:7–26. 2017. View Article : Google Scholar : PubMed/NCBI